三七通舒治疗缺血性脑卒中临床疗效及安全性系统评价

Clinical Efficacy and Safety of Sanqi Tongshu Capsules in Treatment of Ischemic Stroke: A Systematic Review

目的系统评价三七通舒治疗缺血性脑卒中的临床疗效及安全性。方法按照一定的纳入标准和排除标准,在中国知网、中国生物医学文献服务系统、重庆维普网、万方数据知识服务平台上检索三七通舒治疗缺血性脑卒中的相关文献,检索时间截至2012年7月。系统评价文献方法学质量,提取资料,运用ReviewManager 5.1软件进行Meta分析。结果共纳入9篇文献,9篇文献之间无明显异质性(χ2=10.20,自由度=8,P=0.25,I2=22%),比值比=3.34(95%可信区间(2.30,4.84)),Meta分析结果显示试验组与对照组在疗效方面有显著性差异(P<0.01)。结论三七通舒治疗缺血性脑卒中临床效果明显优于常规治疗,值得临床推广。

Objective To evaluate the clinical efficacy and safety of Sanqi Tongshu Capsules,which are prepared from Panax notoginseng and used for promoting blood circulation and removing blood stasis,in the treatment of ischemic stroke by a systematic review.MethodsA literature search was performed using network databases including CNKI,CBM,CQVIP,and Wangfang Data according to certain inclusion and exclusion criteria;the literature included the papers on treatment of ischemic stroke with Sanqi Tongshu Capsules published up to July 2012.The methodological quality of the included studies was evaluated systematically,and relevant data were extracted.A meta-analysis was performed using Review Manager 5.1.ResultsA total of 9 studies were included in the analysis.There were no significant heterogeneity among the studies(χ2= 10.20,degree of freedom=8,P= 0.25,I2=22%).The experimental group(treated with Sanqi Tongshu capsules) showed a significantly better response than the control group(receiving conventional treatment)(OR=3.34,95%,CI=2.30-4.84).ConclusionSanqi Tongshu Capsules have better clinical efficacy than conventional treatment in ischemic stroke and show promise for clinical application.